低分子肝素钠在重度及极重度AECOPD疗效观察  

Efficacy Observation of Low Molecular Weight Heparin in Severe and Above AECOPD

作　　者：周曦[1] 张柏膺[1] 严峻海[1] 

机构地区：[1]上海交通大学附属瑞金医院卢湾分院呼吸内科,上海200020

出　　处：《临床肺科杂志》2012年第10期1767-1768,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨重度及以上AECOPD应用抗凝治疗的临床意义。方法选取60例入住病房的重度及以上AECOPD患者,随机分为实验组(抗凝)30例,对照组30例,均给予常规氧疗、抗感染、解痉平喘、化痰等治疗,实验组同时给予低分子肝素治疗1周。治疗前后分别检查动脉血气分析中PaO2、PaCO2,同时取静脉血测C-反应蛋白浓度(C-RP)。结果抗凝治疗结束后,实验组中动脉血气分析中PaO2、PaCO2较对照组有明显改善,实验组的CRP浓度较对照组下降。两组比较差异均有统计学意义。结论抗凝治疗可以改善重度及以上AECOPD患者的动脉血气分析中PaCO2、PaCO2,同时减轻患者体内炎症反应。Objective To investigate the clinical significance of anticoagulant therapy on severe chronic obstructive pulmonary disease （COPD） with acute exacerbation. Methods 60 cases of severe level or above COPD patients with acute exacerbations were ran- domly divided into experimental groups （anticoagulant） having 30 cases, 30 cases in the control group undergone conventional oxygen therapy, antibiotics, antispasmodic asthma, phlegm and other treatment, and the experimental group at the same time were given low mo- lecular weight heparin for 1 week. Blood oxygen pressure （ PaO2 ） in arterial blood, carbon dioxide partial pressure （ PaCO2 ） and C-reac- tive protein concentration （CRP） before and after treatment were measured. Results After the end of the anticoagulant therapy, PaO2 , PaCO2 in the experimental group had a more significant improvement than those in the control group; CRP in the experimental group de- creased more significantly than that in the control group; and there were significant differences in PaO2 , PaCO2 and CRP between two groups. Conclusions The anticoagulant therapy can improve PaO2 , PaCO2 in severe and above AECOPD, and reduce the inflammatory resDonse.

关 键 词：慢性阻塞性肺疾病 低分子肝素 C反应蛋白 血气分析 

分 类 号：R563.9[医药卫生—呼吸系统]